Zhongyi Biotechnology

Zhongyi Biotechnology Co., Ltd. (hereinafter referred to as "Zhongyi Biotechnology") is a platform-based enterprise in the biomedical high-tech industry approved by the State Administration for Industry and Commerce and established in 2017, focusing on operating the "Israel Life Science Park", with a registered capital of 100 million yuan. Zhongyi Biotechnology has introduced several listed companies or their affiliates as strategic investors. It currently has a professional team of more than 60 people in Changsha, China, a team of 16 in Shenzhen, a team of 18 in Israel (all Israeli nationals), and a team of 8 in the United States (mainly American nationals).
Zhongyi Biotechnology aims to turn intellectual property into assets, then securitize the assets, and then leverage capital to realize the marketization of medical technology. It is committed to introducing innovative medical technology from Israel (and the world) to China, and bringing China's consumer market and capital market opportunities to Israel (and the world), becoming an ecosystem-level enterprise in China's medical technology innovation field, cultivating one medical technology enterprise every year, and achieving a global medical Alibaba platform.